Working... Menu
Trial record 96 of 179 for:    "Lymphomatoid Granulomatosis"

Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00740467
Recruitment Status : Unknown
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : August 25, 2008
Last Update Posted : January 28, 2010
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and cyclophosphamide, together with antithymocyte globulin before a donor stem cell transplant helps stop the growth of cancer and abnormal cells. Giving chemotherapy before or after transplant also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer and abnormal cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well stem cell transplant works in treating patients with hematological cancer or other disorders.

Condition or disease Intervention/treatment Phase
Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Precancerous Condition Biological: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: cyclosporine Drug: fludarabine phosphate Drug: mycophenolate mofetil Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation Phase 2

Detailed Description:



  • Evaluate the incidence of graft acceptance in patients with hematological disorders treated with combined immunosuppression before and after HLA-haploidentical hematopoietic stem cell transplantation.


  • Evaluate efficacy of this regimen in these patients.
  • Evaluate toxicity of this regimen in these patients.
  • Assess survival of patients treated with this regimen.

OUTLINE: This is a multicenter study.

  • Reduced-intensity conditioning: Patients receive fludarabine phosphate IV on days -6 to -1, busulfan IV on days -6 to -5, and anti-thymocyte globulin IV on days -4 to -1.
  • Transplantation: Patients undergo transplantation of donor hematopoietic stem cells on day 0. Patients also receive cyclophosphamide IV on day 3 and filgrastim (G-CSF) beginning on day 4 and continuing until blood counts recover.
  • Immunosuppression: Patients receive cyclosporine IV beginning on day -2 and continuing for 6 months and mycophenolate mofetil 4 times a day on days 4-84.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation
Study Start Date : January 2008
Estimated Primary Completion Date : January 2010

Primary Outcome Measures :
  1. Incidence of graft acceptance

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of any of the following hematological cancers with a poor prognosis:

    • Acute myeloid leukemia meeting 1 of the following criteria:

      • Third complete remission (CR3) or beyond
      • CR2 after an early bone marrow relapse (< 24 months)
      • Refractory disease after ≥ 2 chemotherapy courses of induction therapy
    • Acute lymphoblastic leukemia meeting 1 of the following criteria:

      • CR3 after ≥ 1 bone marrow relapse
      • CR2 after early bone marrow relapse (currently or within 6 months after stopping maintenance therapy)
    • Chronic myelogenous leukemia meeting the following criteria:

      • Accelerated phase
      • Second chronic phase
      • No other treatment options
    • Multiple myeloma meeting the following criteria:

      • Failed conventional therapy (including autologous hematopoietic stem cell transplantation)
      • No other treatment alternatives
    • Chronic lymphocytic leukemia meeting the following criteria:

      • Failed conventional therapy
      • No other treatment alternatives
    • Hodgkin lymphoma meeting the following criteria:

      • Failed conventional therapy
      • No other treatment alternatives
    • Non-Hodgkin lymphoma meeting the following criteria:

      • Failed conventional therapy
      • No other treatment alternatives
  • Not eligible for standard myeloablative allograft due to increased toxicity
  • Healthy related donor available and meeting the following criteria:

    • Brother, sister, father, mother, cousin, uncle, or aunt
    • At least an identical HLA haplotype

      • Identical genotype on 1 haplotype (in terms of HLA-A, B, C, and DR)
      • Different on ≤ 4 alleles on the other haplotype
  • No HLA-identical intra- or extra-familial donor cord blood available within the next 3 months


  • Karnofsky performance status 70-100%
  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No contraindication to allogeneic transplantation, including any of the following:

    • Cardiac systolic ejection fraction < 40%
    • DLCO level limiting use of fludarabine
    • Creatinine clearance < 30 mL/min
    • Transaminases and/or bilirubin > 3 times upper limit of normal (unless due to Gilbert disease or cancer)
    • HIV seropositivity
    • Human T-cell lymphotrophic virus type 1 seropositivity
    • Uncontrolled bacterial, viral, or fungal infection
  • No contraindication to any of the study drugs
  • No prior or concurrent psychiatric illness
  • No other cancer in the past 5 years except for basal cell skin cancer or carcinoma in situ of the cervix
  • No concurrent serious, uncontrolled condition
  • No patients deprived of liberty or subject to legal protection


  • No participation in a study of allografts in the past month

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00740467

Layout table for location information
Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes Recruiting
Marseille, France, 13273
Contact: Contact Person    33-4-91-22-37-54      
Sponsors and Collaborators
Institut Paoli-Calmettes
Layout table for investigator information
Study Chair: Didier Blaise, MD Institut Paoli-Calmettes

Layout table for additonal information Identifier: NCT00740467     History of Changes
Other Study ID Numbers: CDR0000592923
First Posted: August 25, 2008    Key Record Dates
Last Update Posted: January 28, 2010
Last Verified: July 2009

Keywords provided by National Cancer Institute (NCI):
recurrent adult grade III lymphomatoid granulomatosis
recurrent grade I lymphomatoid granulomatosis
recurrent grade II lymphomatoid granulomatosis
graft versus host disease
adult acute myeloid leukemia in remission
adult acute myeloid leukemia with 11q23 (MLL) abnormalities
adult acute myeloid leukemia with inv(16)(p13;q22)
adult acute myeloid leukemia with t(15;17)(q22;q12)
adult acute myeloid leukemia with t(16;16)(p13;q22)
adult acute myeloid leukemia with t(8;21)(q22;q22)
recurrent adult acute myeloid leukemia
adult acute lymphoblastic leukemia in remission
recurrent adult acute lymphoblastic leukemia
accelerated phase chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
refractory multiple myeloma
relapsing chronic myelogenous leukemia
recurrent adult Hodgkin lymphoma
adult nasal type extranodal NK/T-cell lymphoma
anaplastic large cell lymphoma
angioimmunoblastic T-cell lymphoma
extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
nodal marginal zone B-cell lymphoma
recurrent adult Burkitt lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult immunoblastic large cell lymphoma
recurrent adult lymphoblastic lymphoma
recurrent adult T-cell leukemia/lymphoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Graft vs Host Disease
Precancerous Conditions
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Fludarabine phosphate
Antilymphocyte Serum
Mycophenolic Acid
Immunosuppressive Agents
Immunologic Factors